Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
16 4월 2024 - 9:00PM
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading
the space by decoding biology to industrialize drug discovery and
development, announced Najat Khan, PhD, will be its Chief R&D
Officer and Chief Commercial Officer. Dr. Khan will lead
Recursion’s research and development, and build its emerging
commercial capabilities. She has also been appointed to Recursion’s
Board of Directors.
“Najat brings a unique blend of leadership in biological,
chemical, and medical sciences, data science, and business,” said
Chris Gibson, Co-Founder and CEO of Recursion. “More importantly,
she has a vision and passion for transforming drug discovery and
development that complements ours and she has a strong sense of
urgency to accelerate the industry’s future. We are excited to
welcome her as a Recursionaut to drive our portfolio pipeline, as
well as create commercial strategies as we continue to
industrialize the creation of high impact medicines.”
Dr. Khan has deep expertise in the pharmaceutical and healthcare
industry, spanning biological, chemical, and medical science,
computational and data science, and general business leadership,
with a focus on driving substantial patient and business value. As
the Chief Data Science Officer and Global Head of Strategy and
Portfolio Organization, for Innovative Medicine R&D at Johnson
& Johnson, Najat played an integral role with the senior
leadership team in building an industry-leading pipeline that
delivered multiple transformational medicines. She has been a
pioneer in driving the impact of data science/AI at scale while
establishing a top-tier diverse data science team, underpinning her
commitment to innovation and excellence at the intersection of
healthcare and technology. Dr. Khan co-chaired Johnson &
Johnson’s Data Science Council, where she has played a key
leadership role in driving the adoption of data science across the
company to achieve business impact and deploy best practices for
data use, AI, ethics, as well talent recruitment and
development.
“My mission and focus has been to harness the power of science,
data, and AI to revolutionize the way we discover, develop, and
deliver transformative medicines for patients”, said Dr. Khan,
“This seamlessly aligns with Recursion’s goal to pioneer the
burgeoning TechBio sector and decode biology and chemistry to
radically improve lives. I believe their approach represents the
future of our industry, and sets Recursion to be at the forefront
to deliver on this vision. I’m thrilled to be part of Recursion’s
board and leadership team, embarking on this vital mission
together.”
Dr. Khan serves as a board member for Alliance for Artificial
Intelligence in Healthcare and is a Steering Committee member of
the White House’s Moonshot CancerX program to enhance outcomes for
cancer patients. Najat is the founder and co-chair of the Data
Science in Industry Roundtable (DISRUPT) – a cross industry forum
dedicated to driving impact through Data Science. She is an alumna
of University of Pennsylvania with a doctorate in Organic Chemistry
leveraging experimental and computational approaches, has an
undergraduate degree in Computational Chemistry and a minor in
Business / Economics from Colgate University, and is published in
various high-impact journals.
“We are pleased to welcome Najat to the board to guide the
strategic vision of Recursion,” said Dean Li, Co-Founder and Board
Member of Recursion and President, Merck Research Laboratories,
“Najat shares our outlook on how the industry needs to evolve, and
I believe her insight will be highly valuable as we enter the era
of AI enabled drug discovery and development.”
About RecursionRecursion is a clinical stage
TechBio company leading the space by decoding biology to
industrialize drug discovery. Enabling its mission is the Recursion
OS, a platform built across diverse technologies that continuously
expands one of the world’s largest proprietary biological, chemical
and patient-centric datasets. Recursion leverages sophisticated
machine-learning algorithms to distill from its dataset a
collection of trillions of searchable relationships across biology
and chemistry unconstrained by human bias. By commanding massive
experimental scale — up to millions of wet lab experiments weekly —
and massive computational scale — owning and operating one of the
most powerful supercomputers in the world, Recursion is uniting
technology, biology, chemistry and patient-centric data to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Media ContactMedia@Recursion.com
Investor ContactInvestor@Recursion.com
Forward-Looking StatementsThis document
contains information that includes or is based upon
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995, including, without limitation, all
statements that are not historical facts. Forward-looking
statements may or may not include identifying words such as “plan,”
“will,” “expect,” “anticipate,” “intend,” “believe,” “potential,”
“continue,” and similar terms. These statements are subject to
known or unknown risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements, including but not limited to: challenges inherent
in pharmaceutical research and development, including the timing
and results of preclinical and clinical programs, where the risk of
failure is high and failure can occur at any stage prior to or
after regulatory approval due to lack of sufficient efficacy,
safety considerations, or other factors; our ability to leverage
and enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; our ability to obtain, maintain, and enforce
intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; inflation
and other macroeconomic issues; and other risks and uncertainties
such as those described under the heading “Risk Factors” in our
filings with the U.S. Securities and Exchange Commission, including
our Annual Report on Form 10-K. All forward-looking statements are
based on management’s current estimates, projections, and
assumptions, and Recursion undertakes no obligation to correct or
update any such statements, whether as a result of new information,
future developments, or otherwise, except to the extent required by
applicable law.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/21f011ab-bada-4c3e-a55f-d8eabecf35ad
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024